Novartis India Limited
Inspire – BKC, 7th Floor,
Bandra Kurla Complex
Bandra East
Mumbai 400 051
Tel: 0091 22 50243000
Website: www.novartis.in
CIN – L24200MH1947PLC006104
E-mail – india.investors@novartis.com

February 19, 2026

To,
The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Scrip Code: 500 672

Dear Sir/ Madam,

Sub.: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations")

We refer to our separate disclosure of even date to the stock exchange notifying that the promoter of the Company, Novartis AG ("**Seller**"), has entered into the Agreement for the sale and purchase of the Sale Shares in Novartis India Limited ("**SPA**") with WaveRise Investments Limited ("**Acquirer 1**"), ChrysCapital Fund X ("**Acquirer 2**") and Two Infinity Partners ("**Acquirer 3**") (Acquirer 1, Acquirer 2, and Acquirer 3, collectively referred to as the "**Acquirers**") dated February 19, 2026 pursuant to which, the Seller has agreed to sell to the Acquirers and the Acquirers have agreed to acquire from the Seller 1,74,50,680 (One Crore Seventy Four Lakhs Fifty Thousand Six Hundred and Eighty) fully paid-up equity shares of the Company representing 70.68% (seventy point six eight percent) of the paid-up equity share capital of the Company ("**Transaction**").

For the purpose of the Transaction, the Company proposes to enter into a company covenant and warranty deed with the Seller and the Acquirers. Accordingly, at its meeting held today, the Board of Directors of the Company approved the Company's execution of such company covenant and warranty deed, following which such deed was executed by the Company.

In consideration of the above and in accordance with Regulation 30 of the Listing Regulations and the applicable circulars, the details required to be disclosed are enclosed as **Annexure-1**.

We request you to kindly take the above on record.

Yours sincerely,

For **Novartis India Limited**

CHANDNI BHUPENDRA MARU

Digitally signed by CHANDNI BHUPENDRA MARU
Date: 2026.02.19 23:56:46 +05'30'

Chandni Maru
Company Secretary and Compliance Officer
Encl.: as above

Novartis India Limited
Inspire – BKC, 7th Floor,
Bandra Kurla Complex
Bandra East
Mumbai 400 051
Tel: 0091 22 50243000
Website: www.novartis.in
CIN – L24200MH1947PLC006104
E-mail – india.investors@novartis.com

Annexure - 1

Disclosure under Regulation 30 of the Listing Regulations read with Clause 5A of Para A of Part A, Schedule III of the Listing Regulations and the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 issued by SEBI on 30 January 2026

No.	Particulars	Details
a)	If the listed entity is a party to the agreement: i. Details of the counterparties (including name and relationship with the listed entity)	1. **Novartis AG –** The Seller is part of the promoter / promoter group of the Company. 2. **WaveRise Investments Limited**, **ChrysCapital Fund X and Two Infinity Partners –** The Acquirers are not related parties of the Company and do not hold any shares in the Company.
b)	If listed entity is not a party to the agreement: i. Name of the party/ies entering into such an agreement and the relationship with the listed entity ii. Details of the counterparties to the agreement (including name and relationship with the listed entity) iii. Date of entering into the Agreement	Not applicable as the Company is a party to the company covenant and warranty deed ("**Deed**").
c)	Purpose of entering into the agreement;	The Seller has entered into the Agreement for the sale and purchase of the Sale Shares in Novartis India Limited with the Acquirers dated February 19, 2026 ("**SPA**") pursuant to which the Seller has agreed to sell to the Acquirers and the Acquirers have agreed to acquire from the Seller 1,74,50,680 (One Crore Seventy Four Lakhs Fifty Thousand Six Hundred and Eighty) fully paid-up equity shares of the Company representing 70.68% (seventy point six eight percent) of the equity share capital of the Company (the "**Transaction**"). The Company proposes to enter into the Deed in respect of certain obligations of the Company in connection with the Transaction.
d)	Shareholding, if any, in the entity with whom the agreement is executed;	The Company does not hold any equity shares in any of the Acquirers or the Seller.
e)	Significant terms of the agreement (in brief);	• The Company has provided certain customary warranties on a non-recourse basis to the Acquirers in relation to the Company and its business. • The Company has agreed to provide reasonable assistance and information required by the Acquirers in connection with the mandatory open

Novartis India Limited
Inspire – BKC, 7th Floor,
Bandra Kurla Complex
Bandra East
Mumbai 400 051
Tel: 0091 22 50243000
Website: www.novartis.in
CIN – L24200MH1947PLC006104
E-mail – india.investors@novartis.com

No.	Particulars	Details
		offer made by the Acquirers to the public shareholders of the Company as per the provisions of the SEBI (Substantial Acquisition of Shares and Takeover Regulations), 2011, as amended, pursuant to the execution of the SPA for the Transaction. • The Company has agreed to comply with certain customary interim obligations requiring the Company to conduct its affairs in the ordinary and usual course of business until the completion of the Transaction. • The Company has agreed to change its name to remove all references to the Seller group within 120 days from the completion of the Transaction. • The Company has undertaken certain customary post-closing obligations including to complete the relevant regulatory filings in connection with the Transaction.
f)	Extent and the nature of impact on management or control of the listed entity	Pursuant to the completion of the Transaction: (i) the Seller will cease to be a "Promoter" of the Company; and (ii) the Acquirers will acquire control of the Company and will be classified as the "Promoter" of the Company, in accordance with applicable law.
g)	Details and quantification of the restriction or liability imposed upon the listed entity;	Please refer to the paragraph above on paragraph (e) "*Significant terms of the agreement (in brief)*".
h)	Whether the said parties are related to promoter / promoter group / group companies in any manner. If yes, nature of relationship;	As on date, the Seller holds 70.68% (seventy point six eight percent) of the Company's paid up share capital and is part of the promoter / promoter group of the Company.
i)	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length";	No, the Transaction and the Deed are not related party transactions in relation to the Company.
j)	In case of issuance of shares to the parties, details of issue price, class of shares issued;	Not Applicable
k)	Any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc.;	Not Applicable
l)	In case of termination or amendment of agreement, listed entity shall disclose	Not Applicable

Novartis India Limited
Inspire – BKC, 7th Floor,
Bandra Kurla Complex
Bandra East
Mumbai 400 051
Tel: 0091 22 50243000
Website: www.novartis.in
CIN – L24200MH1947PLC006104
E-mail – india.investors@novartis.com

No.	Particulars	Details
	additional details to the stock exchange(s): i. name of parties to the agreement. ii. nature of the agreement. iii. date of execution of the agreement. iv. details and reasons for amendment or alteration and impact thereof (including impact on management or control and on the restriction or liability quantified earlier). v. reasons for rescission and impact thereof (including impact on management or control and on the restriction or liability quantified earlier).	